Halozyme is a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. Our lead proprietary program, investigational drug PEGPH20 (pegvorhyaluronidase alfa), applies a unique approach to targeting solid tumors, potentially providing increased immune response and tumor access for co-administered anti-cancer therapies.In addition to our proprietary product pipeline, Halozyme has value-driving partnerships with leading pharmaceutical companies.
|Bank Name||Halozyme Therapeutics, Inc.|
|Industry||Biotechnology: Biological Products|
|CEO||Dr. Helen I. Torley|